Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study

Autor: Marie-Hélène Dramard-Goasdoue, Stefan Andreas, Hans Hoffmann, Obukohwo Siakpere, Sorrel Wolowacz, Christos Chouaid, Ilias Kontoudis, Costel Chirila, Janina Barth, Mark Price, Sarah Danson, L Benjamin, Vanessa Potter, Fabrice Barlesi, Kelly Hollis, James A. Kaye, Carolyn Sweeney, Rainer Ehness
Přispěvatelé: CHI Créteil, Weston Park Hospital, Georg-August-University = Georg-August-Universität Göttingen, GSK House [Middlesex, London], GlaxoSmithKline [Rueil Malmaison], GSK, Munich, GSK, Marly le Roi, Heidelberg University, Nottingham University Hospitals NHS Trust (NUH), Oncologie multidisciplinaire et innovations thérapeutiques [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], CIC - Biotherapie - Marseille, Institut National de la Santé et de la Recherche Médicale (INSERM), RTI Health Solutions, Research Triangle Institute International (RTI International), GlaxoSmithKline Pharmaceuticals [Rixensart] (GSK)
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Male
Cancer Research
Lung Neoplasms
medicine.medical_treatment
Burden-of-illness
030204 cardiovascular system & hematology
NSCLC
Carboplatin
chemistry.chemical_compound
0302 clinical medicine
Cost of Illness
Carcinoma
Non-Small-Cell Lung
Germany
Observational study
Antineoplastic Combined Chemotherapy Protocols
Neoplasm Metastasis
Stage (cooking)
Pneumonectomy
education.field_of_study
Medical record
Vinorelbine
3. Good health
Treatment Outcome
Oncology
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Female
France
Adjuvant
medicine.drug
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Population
[SDV.CAN]Life Sciences [q-bio]/Cancer
Adjuvant therapy
03 medical and health sciences
Internal medicine
medicine
Humans
Lung cancer
education
Aged
Neoplasm Staging
business.industry
medicine.disease
Survival Analysis
United Kingdom
chemistry
Cisplatin
Neoplasm Recurrence
Local
business
Follow-Up Studies
Zdroj: Lung Cancer
Lung Cancer, 2018, 124, pp.310-316. ⟨10.1016/j.lungcan.2018.07.042⟩
ISSN: 0169-5002
Popis: International audience; Objectives: To inform health-technology assessments of new adjuvant treatments, we describe treatment patterns in patients with complete resection of stage IB-IIIA non-small cell lung cancer (NSCLC) in France, Germany, and the United Kingdom (UK).Materials and methods: Data were collected via medical record abstraction. Patients were aged ≥18 years with completely resected stage IB-IIIA NSCLC, diagnosed between 01 January 2009 and 31 December 2011. Median follow-up was 26 months. Adjuvant treatment patterns and clinical outcomes were summarized descriptively.Results: Among the 831 patients studied, 239 (29%) had stage IB disease, 179 (22%) had stage IIA disease, 165 (20%) had stage IIB disease, and 248 (30%) had stage IIIA disease. Adjuvant systemic therapy was received by 402 patients (48.4%), (France, 61.8%; Germany, 51.9%; UK, 33.4%). Use of adjuvant therapy increased with increasing stage of disease. Cisplatin/vinorelbine and carboplatin/vinorelbine were the most frequently prescribed adjuvant regimens. Median disease-free survival was 48.0 months (95% confidence interval [CI] 42.3-not estimable); the 25th percentile was 13.2 months (95% CI, 11.0-15.3). 204 patients (24%) died during the follow-up period. The median overall survival was not reached, the 25th percentile was 31.2 months (95% CI 26.8-36.0 months). 272 patients (33%) had disease recurrence during the follow-up period. For 86 of those patients, the first recurrence was local or regional with no distant metastasis and 14 had further progression to metastatic disease during the follow-up time. For the other 186 patients, the first recurrence involved distant metastases. A total of 200 patients had metastatic disease at any time during study follow-up.Conclusions: Less than half the patients with stage IB-IIIA NSCLC in this observational study received adjuvant systemic therapy. A high rate of first recurrence with distant metastatic disease was observed, emphasising the need for more effective systemic adjuvant therapies in this population.
Databáze: OpenAIRE
Externí odkaz: